Skip to main content
    C

    Cardiol Therapeutics Inc Class A (CRDL)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.97
    -0.01 (-0.82%)

    Market Cap: $127.69M

    Last updated: Nov 17, 2026 at 4:22 PM ET

    Cardiol Therapeutics Inc Class A (CRDL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cardiol Therapeutics Inc Class A (CRDL) has a market cap of $127.69M. Its share count is up 39.30% from a year earlier.

    Total Valuation

    Market Cap$127.69M
    Latest price (Nov 17, 2026)$0.97

    Key Dates

    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.69% in the quarter ended Sep 30, 2026 and grew 30.00% a year over 2 years.

    Shares Outstanding118.03M
    Share ClassClass A
    Shares Change (YoY)+39.30%
    Shares Change (QoQ)+2.69%
    Share Count Growth (2Y CAGR)+30.00%

    Price Statistics

    The stock is down 4.73% over 52 weeks and trades 29.20% below its 50-day average.

    Beta (1Y)1.27
    52-Week Change-4.73%
    1-Month Change-11.65%
    3-Month Change-50.42%
    6-Month Change-22.87%
    5-Year Change-69.34%
    Total Return (1Y)-4.73%
    Total Return (5Y CAGR)-14.61%
    Max Drawdown (1Y)-59.45%
    Max Drawdown (3Y)-72.73%
    Sharpe Ratio (1Y)-0.09
    Correlation with SPY (1Y)0.28
    50-Day Average$1.37
    200-Day Average$1.30
    52-Week Range$0.88 to $2.34
    RSI (14 Days)32.4
    Average Volume (20 Days)542.60K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.26x current liabilities.

    Current Ratio6.26x
    Quick Ratio6.26x

    Returns and Efficiency

    Return on equity is -145.15% and return on assets is -121.84% over the last 12 months.

    Return on Equity (ROE)-145.15%
    Return on Assets (ROA)-121.84%
    Return on Capital Employed (ROCE)-131.67%
    ROA (5Y Average)-78.89%
    ROIC (5Y Average)-80.69%

    Scores

    CRDL has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was CAD 0 over the last 12 months.

    RevenueCAD 0
    Operating IncomeCAD -38.59M
    Pretax IncomeCAD -39.96M
    Net IncomeCAD -39.68M
    EBITDACAD -36.47M
    EBITCAD -36.55M

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 83.94% of the CAD 33.00M in total assets.

    Working CapitalCAD 27.61M
    Shareholder EquityCAD 27.70M
    Total AssetsCAD 33.00M
    Total LiabilitiesCAD 5.30M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After CAD 77.80K of capital spending, operating cash flow left CAD -21.68M of free cash flow.

    Operating Cash FlowCAD -21.60M
    Capital ExpendituresCAD 77.80K
    Free Cash FlowCAD -21.68M
    Depreciation and AmortizationCAD 77.08K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CRDL

    What is CRDL's market cap?

    Cardiol Therapeutics Inc Class A has a market cap of $127.69M.

    How many shares of CRDL are outstanding?

    Cardiol Therapeutics Inc Class A has 118.03M shares outstanding. The count is up 39.30% from a year earlier.

    Does CRDL pay a dividend?

    No. Cardiol Therapeutics Inc Class A does not pay a dividend.